Companies /Healthcare

Ultragenyx Pharmaceutical Inc

NASDAQ: RARE Biotechnology
$16.48
▼ $0.74 (−4.30%) today
Markets closed · 9:56pm ET

24/7 Wall St. View

RARE at a Glance

Valuation
Market cap
$1.8B
Profitability
Revenue (TTM)
$730.0M
Profit margin
-71.8%
EPS (TTM)
$-5.17
Price
52-week range
$13 – $40
24/7 target
$29.56
Street target
$24.80
Earnings
Next report
Feb 10, 2027

Headquartered in Novato, CA Fiscal year ends December NASDAQ: RARE ultragenyx.com

About Ultragenyx

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a biopharmaceutical company that develops and commercializes novel therapies for serious rare and ultra-rare genetic diseases with high unmet medical need and clear biology.

Its commercial portfolio includes:
- CRYSVITA (burosumab) for X-linked hypophosphatemia. Kyowa Kirin commercializes it in the U.S., Canada and Europe, paying royalties to Ultragenyx, while Ultragenyx records product sales in Latin America and Türkiye.
- DOJOLVI.
- EVKEEZA.
- MEPSEVII.
- Two newly FDA-approved AAV gene therapies: GENGLYCOS for glycogen storage disease type Ia (accelerated approval, August 2026) and FAYUVI for Sanfilippo syndrome type A (full approval, September 2026).

Revenue comes from product sales and royalties.

After completing its late-stage programs, the company is restructuring toward commercial execution and a smaller R&D footprint. It is cutting headcount by about 20% to roughly 1,000 employees and ending the GTX-102 and UX701 programs. Its remaining pipeline focus is DTX301 for OTC deficiency, UX143 (setrusumab) for osteogenesis imperfecta, UX016 for GNE myopathy, and early-stage programs. Updated

RARE Coverage

Frequently Asked Questions

What does Ultragenyx do?

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is a biopharmaceutical company that develops and commercializes novel therapies for serious rare and ultra-rare genetic diseases with high unmet medical need and clear biology. Its commercial portfolio includes: - CRYSVITA (burosumab) for X-linked hypophosphatemia.

What is the RARE stock price target?

24/7 Wall St.'s 12-month price target for RARE is $29.56, rated Buy. The Wall Street consensus target is $24.80. RARE price prediction →